Clinical Case Webinars

Monthly case-based discussions providing a continuing learning environment on clinical matters related to prescribing methadone or buprenorphine pharmacotherapies for opioid dependence. Register for one of our upcoming webinars or view previous session recordings.

Want to be notified when new webinars are coming up?

Make sure you’re on our mailing list –  Join Here


Join us for our next OTAC Clinical Case Webinar 

In this session, we will discuss the S100 Changes 12 Months On. Leading the session is Prof Paul Haber. This session is taking place on Tuesday, 25th June 2024 @ 6pm via Zoom.

Have a question or a suggested case? You can submit this prior to the session by completing the Clinical Case Webinar submission form.

Upcoming Webinars

Upcoming Webinars (Tuesdays @ 6pm)

Previous Webinar Recordings

2024 Webinars

In this session, we discussed the management of medicinal and non-medical cannabis use in OAT settings.

The session was led by Prof Nick Lintzeris, Senior Staff Specialist, Drug and Alcohol Services, South East Sydney Local Health District and Conjoint Professor of Addiction Medicine at the University of Sydney.

Webinar Resources


Presentation slides available soon.


Resources

  • SafeScript NSW is a clinical tool that provides prescribers and pharmacists with real time information about their patient’s prescribing and dispensing history for monitored medicines.
  • Clinician Advice Line is a free 24/7 clinical telephone advice service has been established to support prescribers and pharmacists. Assistance includes access to clinical advice for addiction medicine, pain management and mental health, safe de-escalation of high doses of benzodiazepines and opioids, and appropriate management and referral to other clinical services where required.
  • Drug & Alcohol Specialist Advisory Service (DASAS) assists health professionals seeking advice about the diagnosis and treatment of patients with alcohol or drug issues in NSW, and is a free service available 24 hours a day, 7 days a week.

In this session, we discussed methods and options when providing harm reduction services to people receiving Opioid Agonist Treatment (OAT).

The session was led by Dr Merissa Cappetta, GP and Addiction Specialist working at Kirketon Road Centre, Lucy Pepolim, NUAA Peer Worker Lead, and Tony McNaughton, NUAA HCV Peer Specialist Worker.

Resources

  • Where To Access Take Home Naloxone (THN)
  • NUAA Overdose Response with NaloxoneNUAA provides video instructions on how to use the Nyxoid Nassal Spray and Prenoxad Injectable
  • NUAA PeerLine 1800 644 413
  • SafeScript NSW is a clinical tool that provides prescribers and pharmacists with real time information about their patient’s prescribing and dispensing history for monitored medicines.
  • Clinician Advice Line is a free 24/7 clinical telephone advice service has been established to support prescribers and pharmacists. Assistance includes access to clinical advice for addiction medicine, pain management and mental health, safe de-escalation of high doses of benzodiazepines and opioids, and appropriate management and referral to other clinical services where required.
  • Drug & Alcohol Specialist Advisory Service (DASAS) assists health professionals seeking advice about the diagnosis and treatment of patients with alcohol or drug issues in NSW, and is a free service available 24 hours a day, 7 days a week.

In this session, we discussed the steps that occur when someone on OAT is first placed in custody, how OAT functions within custodial settings, and the pathways for people on OAT when released from custody.

The session was led by staff from the Justice Health and Forensic Mental Health Network (JH&FMHN), including Dr Katerina Lagios, Dr Peter Thompson, Craig Cooper, Anthony Lamproglou.

Resources

  • SafeScript NSW is a clinical tool that provides prescribers and pharmacists with real time information about their patient’s prescribing and dispensing history for monitored medicines.
  • Clinician Advice Line is a free 24/7 clinical telephone advice service has been established to support prescribers and pharmacists. Assistance includes access to clinical advice for addiction medicine, pain management and mental health, safe de-escalation of high doses of benzodiazepines and opioids, and appropriate management and referral to other clinical services where required.
  • Drug & Alcohol Specialist Advisory Service (DASAS) assists health professionals seeking advice about the diagnosis and treatment of patients with alcohol or drug issues in NSW, and is a free service available 24 hours a day, 7 days a week.

For the first OTAC Webinars for 2024, examined the important updates to SafeScript NSW regarding Opioid Treatment Program (OTP) approvals. These new changes simplify the process for entering a patient onto treatment, often allowing for faster approvals and will eventually replace paper-based forms. Included within this webinar, was a demonstration of the changes that allow for a patient to be approved for OTP on SafeScript NSW.

This session was held in February 2024, and led by the SafeScript NSW Program Team at eHealth NSW. To contact the SafeScript NSW Program Team, email: safescript@health.nsw.gov.au.

Resources

  • SafeScript NSW is a clinical tool that provides prescribers and pharmacists with real time information about their patient’s prescribing and dispensing history for monitored medicines.
    • About approval management: The new SafeScript NSW approval management functionality simplifies the way prescribers apply for and manage approvals for certain high-risk medicines.
    • Applying for approval: The SafeScript NSW approval management functionality will allow prescribers to apply to prescribe or supply under the Opioid Treatment Program (OTP) and apply to prescribe Schedule 8 psychostimulants.
    • Support Resources: How to videos are available to guide you through key components of the approval management functionality within SafeScript NSW.
  • Clinician Advice Line is a free 24/7 clinical telephone advice service has been established to support prescribers and pharmacists. Assistance includes access to clinical advice for addiction medicine, pain management and mental health, safe de-escalation of high doses of benzodiazepines and opioids, and appropriate management and referral to other clinical services where required.
  • Drug & Alcohol Specialist Advisory Service (DASAS) assists health professionals seeking advice about the diagnosis and treatment of patients with alcohol or drug issues in NSW, and is a free service available 24 hours a day, 7 days a week.

2023 Webinars

For the final session of 2023 we looked at planned leave for prescribers and clients, and preparations for instances of unplanned leave. This includes information both planned leave, unplanned leave and retirement for prescribers, along with details regarding planned or sudden travel requirements for clients, including interstate and overseas provisions. 

Leading the session is Prof Paul Haber, Addiction Medicine Specialist and Clinical Director of Drug Health Services in Sydney Local Health District. Prof Haber is also the Clinical Lead of the OTAC Program at the University of Sydney Speciality of Addiction Medicine.

NSW Clinical Guidelines: Treatment of Opioid Dependence

 

 


Clinical guidelines for depot buprenorphine in the treatment of opioid dependence

 

 


Other Resources

  • INDRO e.V. Travel Guide Index has select information regarding the provision of methadone and buprenorphine for opioid dependence whilst travelling overseas for some countries. Whilst this can be used as an inital resource, prescribers and clients should also contract local embassies or consulates for further guidance.
  • NSW Health Mandatory Notifications for OTP include instances where there is a change in dosing point, locum arrangements during planned leave, when clients are travelling overseas, and when you are planning for retirement/or are no longer planning to prescribe opioid agonist treatment.
  • Interstate contacts for client transfers are also provided by NSW Health. You should reach out to the relevant state or territory contact for information about temporary or permanant transfers of OTP clients.
  • Drug & Alcohol Specialist Advisory Service (DASAS) assists health professionals seeking advice about the diagnosis and treatment of patients with alcohol or drug issues in NSW, and is a free service available 24 hours a day, 7 days a week.

In this session, we examined QT Prolongation, which is a potential, but uncommon, issue that can arise when prescribed opioid agonist treatment. We discussed what QT Prolongation is and how to identify it, other factors that may need to be considered, key drug-drug interactions that are of relevance, and how to respond to elevated QT prolongation.

The session, held in October, was led by Dr David Yoo, Addiction Medicine Advanced Trainee based at Drug Health Services in Sydney Local Health District. Joining in the conversation was Dr Sharon Reid, Medical Officer & OTAC Clinical Academic Advisor, from the University of Sydney Specialty of Addiction Medicine & Drug Health Services, Sydney Local Health District.

NSW Clinical Guidelines: Treatment of Opioid Dependence

 

 

 

 

 


Clinical Guidelines for depot buprenorphine (Buvidal® and Sublocade®) in the treatment of opioid dependence

 

 

 

 


Resources

  • SafeScript NSW is a clinical tool that provides prescribers and pharmacists with real time information about their patient’s prescribing and dispensing history for monitored medicines.
  • Clinician Advice Line is a free 24/7 clinical telephone advice service has been established to support prescribers and pharmacists as part of the rollout of SafeScript NSW. Assistance includes access to clinical advice for addiction medicine, pain management and mental health, safe de-escalation of high doses of benzodiazepines and opioids, and appropriate management and referral to other clinical services where required.
  • Drug & Alcohol Specialist Advisory Service (DASAS) assists health professionals seeking advice about the diagnosis and treatment of patients with alcohol or drug issues in NSW, and is a free service available 24 hours a day, 7 days a week.

In this session, we examined cases around chronic pain management and OAT, including for those who are already receiving OAT and when it may be appropriate to consider providing OAT for a patient with chronic prescription opioid use.

The session, held in October, was led by Prof Apo Demirkol, Senior Staff Specialist of Drug and Alcohol Services & the Prince of Wales Hospital Pain Management Centre in South Eastern Sydney LHD, and Conjoint Professor in the School of Public Health and Community Medicine at UNSW.

NSW Clinical Guidelines: Treatment of Opioid Dependence

 

 

 

 

 


Clinical Guidelines for depot buprenorphine (Buvidal® and Sublocade®) in the treatment of opioid dependence

 

 

 

 


Resources

  • Application for Authority to Prescribe or Supply a Schedule 8 Drug-Pain Management is to be used if you intend to prescribe a Schedule 8 opioid (e.g. oxycodone, morphine or fentanyl) or another S8 drug for the management of pain in a patient, as required under the NSW Poisons and Therapeutic Goods Act 1966. Additional information on this form is found on the NSW Ministry of Health Website.
  • SafeScript NSW is a clinical tool that provides prescribers and pharmacists with real time information about their patient’s prescribing and dispensing history for monitored medicines.
  • Clinician Advice Line is a free 24/7 clinical telephone advice service has been established to support prescribers and pharmacists as part of the rollout of SafeScript NSW. Assistance includes access to clinical advice for addiction medicine, pain management and mental health, safe de-escalation of high doses of benzodiazepines and opioids, and appropriate management and referral to other clinical services where required.
  • Drug & Alcohol Specialist Advisory Service (DASAS) assists health professionals seeking advice about the diagnosis and treatment of patients with alcohol or drug issues in NSW, and is a free service available 24 hours a day, 7 days a week.

In this session, we discuss navigating the provision of opioid agonist treatment (OAT) within the general practice setting. We will explore when, and how to prescribe OAT to clients in different scenarios including those who are already on OAT, and those seeking to start treatment.

This session, held in September, was led by Dr Hester Wilson, a Fellow of the RACGP, a Fellow of Chapter of Addiction Medicine in the Royal Australasian College of Physicians and Chair of the RACGP’s Specific Interest Group in Addiction. Joining in the conversation was Dr May Su, a Fellow of the RACGP, Chair of the RACGP Specific Interest Group Abuse and Violence in Families and is an Australian General Practice Training Supervisor and a Royal Australian College of General Practice Examiner.

Resources

  • SafeScript NSW is a clinical tool that provides prescribers and pharmacists with real time information about their patient’s prescribing and dispensing history for monitored medicines.
  • Clinician Advice Line is a free 24/7 clinical telephone advice service has been established to support prescribers and pharmacists as part of the rollout of SafeScript NSW. Assistance includes access to clinical advice for addiction medicine, pain management and mental health, safe de-escalation of high doses of benzodiazepines and opioids, and appropriate management and referral to other clinical services where required.
  • Drug & Alcohol Specialist Advisory Service (DASAS) assists health professionals seeking advice about the diagnosis and treatment of patients with alcohol or drug issues in NSW, and is a free service available 24 hours a day, 7 days a week.

In this session, we discuss the role of SafeScript NSW for health professionals who provide patients with opioid agonist treatment (OAT), and includes an overview of SafeScript NSW complemented by OAT-related cases using how SafeScript may be used to inform your practice.

This session, held in August 2023, was led by Stephen Ling, Nurse Practitioner in Drug and Alcohol at John Hunter Hospital, Hunter New England LHD. Stephen is also a Clinical Analyst for the Real Time Prescription Monitoring Program with eHealth NSW. Joining the session included Dr Sharon Reid, Medical Officer & OTAC Clinical Academic Advisor, and Mr Daniel Winter, OTAC Coordinator, both from the University of Sydney Specialty of Addiction Medicine & Drug Health Services, Sydney Local Health District.

Resources

  • SafeScript NSW is a clinical tool that provides prescribers and pharmacists with real time information about their patient’s prescribing and dispensing history for monitored medicines.
    • How to Register for SafeScript NSW: Registration is now available for all APHRA registered prescribers and pharmacists practicing in NSW.
    • Education and Training: Access several eLearning modules and training about the SafeScript NSW System and more. The modules are accredited as part of Continuing Professional Development (CPD) for doctors, pharmacists and nurse practitioners.
    • Information for Patients: Prescribers and pharmacists can find useful resources to share with their patients about SafeScript NSW and monitored medicines.
  • Clinician Advice Line is a free 24/7 clinical telephone advice service has been established to support prescribers and pharmacists. Assistance includes access to clinical advice for addiction medicine, pain management and mental health, safe de-escalation of high doses of benzodiazepines and opioids, and appropriate management and referral to other clinical services where required.
  • Drug & Alcohol Specialist Advisory Service (DASAS) assists health professionals seeking advice about the diagnosis and treatment of patients with alcohol or drug issues in NSW, and is a free service available 24 hours a day, 7 days a week.

In this session, we discuss acute pain management consideration for OAT clients, including an overview of several cases that you may come across in your clinical practice, from mild to more severe acute pain, and perioperative pain management.

This session, held in July 2023, was led by Dr Joshua Watt, General Practitioner Specialist and Addiction Medicine Advanced Trainee at Sydney Local Health District Drug Health Services. Joining the session included Dr Sharon Reid, Medical Officer & OTAC Clinical Academic Advisor, and Mr Daniel Winter, OTAC Coordinator, both from the University of Sydney Specialty of Addiction Medicine & Drug Health Services, Sydney Local Health District.

Webinar Resources


Download presentation slides (PDF)

 

 

 


NSW Clinical Guidelines: Treatment of Opioid Dependence

 

 

 

 

 


Clinical Guidelines for depot buprenorphine (Buvidal® and Sublocade®) in the treatment of opioid dependence

 

 

 

 


Other Resources

  • Application for Authority to Prescribe or Supply a Schedule 8 Drug-Pain Management is to be used if you intend to prescribe a Schedule 8 opioid (e.g. oxycodone, morphine or fentanyl) or another S8 drug for the management of pain in a patient, as required under the NSW Poisons and Therapeutic Goods Act 1966. Additional information on this form is found on the NSW Ministry of Health Website.
  • SafeScript NSW is a clinical tool that provides prescribers and pharmacists with real time information about their patient’s prescribing and dispensing history for monitored medicines.
  • Clinician Advice Line is a free 24/7 clinical telephone advice service has been established to support prescribers and pharmacists. Assistance includes access to clinical advice for addiction medicine, pain management and mental health, safe de-escalation of high doses of benzodiazepines and opioids, and appropriate management and referral to other clinical services where required.
  • Drug & Alcohol Specialist Advisory Service (DASAS) assists health professionals seeking advice about the diagnosis and treatment of patients with alcohol or drug issues in NSW, and is a free service available 24 hours a day, 7 days a week.

Following a announcement by the Federal Government in the 2023 Budget, major changes to the funding of medications under the opioid treatment program (which include methadone and buprenorphine pharmacotherapies for the treatment of opioid use disorder) commence on 1 July 2023. 

In this special webinar Q&A session, we will provide an update on this announcement and what it may mean for health professionals who provide opioid treatment pharmacotherapies in various settings within New South Wales.

Leading the discussion will be Prof Paul Haber, Clinical Director of Drug Health Services SLHD & Head of the Specialty of Addiction Medicine at the University of Sydney. We also hear from representatives from the NSW Ministry of Health and professional stakeholders that provide opioid agonist treatment.

Webinar Resources


We will aim to provide the most recent information related to these changes, but note that some information may no longer be current in the recording or in the presented fact sheets. Any major changes that occur since this recording will be summarised here.


In this session, we discuss the common clinical challenges that you may experience when providing clinical care to people who are prescribed opioid agonist treatment pharmacotherapies.

This session, held in May 2023, was led by Prof Paul Haber, Head of Specialty of Addiction Medicine, University of Sydney & Clinical Director of Sydney Local Health District Drug Health Services. Prof Haber is also the academic lead of the OTAC Program. Four cases are presented to highlight key clinical considerations, with cases related to a patient in prison, a patient with few medial record details, a routine clinical appointment, and a positive urine drug screen. 

Webinar Resources


Download presentation slides (PDF)

 

 

 

 


In this session, we discuss a range of sedating substances and how they can impact on OAT, how can we best manage patients on OAT who are also using sedating substances, and how to manage patients on OAT with polysubstance use.

Leading this session was Dr Rowena Penafiel, Advanced Trainee in Clinical Pharmacology, Toxicology and Addiction Medicine at Drug Health Services, Sydney Local Health District. Joining in the conversation included over 70 attendees for this session, alongside Dr Sharon Reid, Medical Officer & OTAC Clinical Academic Advisor, and Mr Daniel Winter, OTAC Coordinator, both from the University of Sydney Specialty of Addiction Medicine & Drug Health Services, Sydney Local Health District.


Webinar Resources

 

Download presentation slides (PDF)

 

 

 


Clinical Guidelines for depot buprenorphine (Buvidal® and Sublocade®) in the treatment of opioid dependence

 

 

 


Other Resources

  • SafeScript NSW is a clinical tool that provides prescribers and pharmacists with real time information about their patient’s prescribing and dispensing history for monitored medicines
  • Clinician Advice Line is a free 24/7 clinical telephone advice service has been established to support prescribers and pharmacists. Assistance includes access to clinical advice for addiction medicine, pain management and mental health, safe de-escalation of high doses of benzodiazepines and opioids, and appropriate management and referral to other clinical services where required.
  • Drug & Alcohol Specialist Advisory Service (DASAS) assists health professionals seeking advice about the diagnosis and treatment of patients with alcohol or drug issues in NSW, and is a free service available 24 hours a day, 7 days a week.

In this session, we discuss key the challenges you may come across when transferring a patient to buprenorphine pharmacotherapies for treating opioid dependence, including highlighting the potential role for microdosing transfers. What are the options for buprenorphine transfers and initiation? What factors can complicate initiation onto buprenorphine and how do we manage them?

Leading this session was Dr Chris Tremonti, Addiction Specialist and Clinical Pharmacologist at St Vincent’s Drug and Alcohol Services. Joining in the conversation included over 75 attendees for this session, alongside Dr Sharon Reid, Medical Officer & OTAC Clinical Academic Advisor, and Mr Daniel Winter, OTAC Coordinator, both from the University of Sydney Specialty of Addiction Medicine & Drug Health Services, Sydney Local Health District.

Webinar Resources


Download presentation slides (PDF)

 

 

 

 


NSW Clinical Guidelines: Treatment of
Opioid Dependence

Hard copies of the guidelines can be requested from:
moh-populationhealthresources@health.nsw.gov.au


Clinical Guidelines for depot buprenorphine (Buvidal® and Sublocade®) in the treatment of opioid dependence

2022 Webinars

This webinar topic was on switching between & within OAT pharmacotherapies, facilitated by: Dr Joshua Watt, Dr Sharon Reid, Mr Daniel Winter, of the Specialty of Addiction Medicine, University of Sydney & Sydney Local Health District Drug Health Services. This session was recorded on Tuesday 22nd November 2022.

In this webinar, we discuss what clinicians should consider when transferring a patient between methadone, sublingual buprenorphine or depot buprenorphine pharmacotherapies. Within the discussion we reflect upon clinical considerations that may impact on medication choice, including common pitfalls, patient preference, and patients who may be pregnant.

This webinar topic was on OAT takeaway connundrums, facilitated by: Prof Paul Haber, Dr Sharon Reid, Mr Daniel Winter of the Specialty of Addiction Medicine, University of Sydney & Sydney Local Health District Drug Health Services. This session was recorded on Tuesday 6th September 2022.

In this webinar, we discuss the clinical conundrums to consider around providing takeaways to a patient on OAT. What are the risks and benefits of providing takeaways? What should you do if you need to consider going outside the guidance for takeaways? We also ask the audience what their experiences have been in providing takeaways to patients, or what challenges that they have faced in their clinical practice.